Thor Medical
Oslo
About Thor Medical
Thor Medical ASA is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $38.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: ose:NANOV
- Website: thormedical.com
- Phone: +47 22 18 33 01
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/thor-medical-20794 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.